- Global Operation
- Contract Manufacturing
Mycophenolate Mofetil acts by blocking purine synthesis of human lymphocytes through reversible inhibition of inosine monophosphate dehydrogenase. It also inhibits proliferation of both T and B-lymphocytes. The mean absolute bioavailability of oral Mycophenolate Mofetil relative to intravenous Mycophenolate Mofetil was 94%. Orally administered radiolabeled Mycophenolate Mofetil resulted in complete recovery of the administered dose, with 93% in the urine and 6% in feces.
Indications and Usage
Mycophenolate Mofetil is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. Mycophenolate Mofetil should be used concomitantly with other immunosuppressants.
GraftceptÂ® Tablet 500 mg: Each commercial box contains 30 tablets in Alu-Alu blister pack.